TESARO Stock Price, News & Analysis (NASDAQ:TSRO)

$65.52 -4.07 (-5.85 %)
(As of 01/17/2018 06:04 AM ET)
Previous Close$69.59
Today's Range$63.00 - $68.64
52-Week Range$63.00 - $192.94
Volume3.27 million shs
Average Volume1.31 million shs
Market Capitalization$3.56 billion
P/E Ratio-7.77
Dividend YieldN/A
Beta1.51

About TESARO (NASDAQ:TSRO)

TESARO logoTESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Receive TSRO News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:TSRO
CUSIP88156910
Phone+1-339-9700900

Debt

Debt-to-Equity Ratio0.34%
Current Ratio4.73%
Quick Ratio4.35%

Price-To-Earnings

Trailing P/E Ratio-7.77224199288256
Forward P/E Ratio-8.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$44.82 million
Price / Sales79.50
Cash FlowN/A
Price / CashN/A
Book Value$11.44 per share
Price / Book5.73

Profitability

Trailing EPS($8.43)
Net Income$-387,470,000.00
Net Margins-251.22%
Return on Equity-93.39%
Return on Assets-61.53%

Miscellaneous

Employees446
Outstanding Shares54,380,000

TESARO (NASDAQ:TSRO) Frequently Asked Questions

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

How were TESARO's earnings last quarter?

TESARO Inc (NASDAQ:TSRO) announced its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.16) by $0.69. The biopharmaceutical company had revenue of $142.77 million for the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. TESARO's revenue was up 740.3% compared to the same quarter last year. During the same quarter last year, the business earned ($1.72) earnings per share. View TESARO's Earnings History.

When will TESARO make its next earnings announcement?

TESARO is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for TESARO.

Where is TESARO's stock going? Where will TESARO's stock price be in 2018?

23 Wall Street analysts have issued twelve-month target prices for TESARO's shares. Their forecasts range from $80.00 to $236.00. On average, they anticipate TESARO's stock price to reach $151.13 in the next twelve months. View Analyst Ratings for TESARO.

What are Wall Street analysts saying about TESARO stock?

Here are some recent quotes from research analysts about TESARO stock:

  • 1. HC Wainwright analysts commented, "Updates to Varubi’s Label; Reiterate Buy and $158 Price Target Prescribing information update, no products being recalled. After the close on January 12, TESARO announced that it has updated the Varubi injectable emulsion package insert in collaboration with the FDA. The changes to the label include modifications to the Contradictions, Warnings and Precuations, and Adverse Reactions section to inclde anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions associated with the use of Varubi injectable emulsion. The company indicated that anaphylaxis, anaphylactic shock and other hypersensitivity reactions have been reported in the postmarketing setting, with some cases requiring hospitalization. These side effects were noted during or soon after the infusion of Varubi, with most reactions observed during the first few minutes of administration." (1/12/2018)
  • 2. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (1/11/2018)
  • 3. Cann analysts commented, "Total Q3 revenue of $142.8 million included a $100 million upfront payment. Net of the upfront payment, revenue was 27.4% higher than our estimated $33.6 million due to stronger than estimated Zejula sales. Total operating expenses of $164.9 million were 3.0% lower than our estimated $170.0 million due to lower than estimated R&D expense. Due to the combination of higher than estimated revenue and slightly lower expenses, Tesaro lost $0.47 per share compared to our estimated loss per share of $2.56." (11/7/2017)
  • 4. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
  • 5. Cowen Inc analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)

Who are some of TESARO's key competitors?

Who are TESARO's key executives?

TESARO's management team includes the folowing people:

  • David M. Mott, Independent Chairman of the Board (Age 51)
  • Mary Lynne Hedley Ph.D., President, Chief Operating Officer, Director (Age 54)
  • Leon O. Moulder Jr., Chief Executive Officer, Director (Age 59)
  • Timothy R. Pearson, Chief Financial Officer, Executive Vice President, Principal Accounting Officer (Age 49)
  • Jeffrey H. Hanke Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer (Age 59)
  • Joseph L. Farmer, Senior Vice President, General Counsel, Secretary (Age 45)
  • Grant C. Bogle, Senior Vice President, Chief Commercial Officer (Age 59)
  • Martin H. Huber M.D., Senior Vice President and Chief Medical Officer (Age 57)
  • Lawrence M. Alleva, Independent Director (Age 67)
  • James O. Armitage M.D., Independent Director (Age 70)

Who owns TESARO stock?

TESARO's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.02%). Company insiders that own TESARO stock include Arnold L Oronsky, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Jeffrey H Hanke, Martin H Jr Huber, Mary Lynne Hedley and Orlando Oliveira. View Institutional Ownership Trends for TESARO.

Who bought TESARO stock? Who is buying TESARO stock?

TESARO's stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have bought TESARO stock in the last two years include Arnold L Oronsky and Enterprise Associates 13 L New. View Insider Buying and Selling for TESARO.

How do I buy TESARO stock?

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TESARO's stock price today?

One share of TESARO stock can currently be purchased for approximately $65.52.

How big of a company is TESARO?

TESARO has a market capitalization of $3.56 billion and generates $44.82 million in revenue each year. The biopharmaceutical company earns $-387,470,000.00 in net income (profit) each year or ($8.43) on an earnings per share basis. TESARO employs 446 workers across the globe.

How can I contact TESARO?

TESARO's mailing address is 1000 Winter St Ste 3300, WALTHAM, MA 02451-1230, United States. The biopharmaceutical company can be reached via phone at +1-339-9700900.


MarketBeat Community Rating for TESARO (TSRO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  445 (Vote Outperform)
Underperform Votes:  266 (Vote Underperform)
Total Votes:  711
MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

TESARO (NASDAQ:TSRO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.582.582.612.64
Ratings Breakdown: 0 Sell Rating(s)
10 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $151.13$158.57$169.82$173.52
Price Target Upside: 133.44% upside94.51% upside44.02% upside39.92% upside

TESARO (NASDAQ:TSRO) Consensus Price Target History

Price Target History for TESARO (NASDAQ:TSRO)

TESARO (NASDAQ:TSRO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018Morgan StanleyLower Price TargetOverweight$165.00 -> $156.00HighView Rating Details
1/12/2018HC WainwrightReiterated RatingBuy$158.00HighView Rating Details
1/2/2018CowenLower Price TargetMarket Perform$125.00 -> $80.00LowView Rating Details
1/2/2018Piper Jaffray CompaniesReiterated RatingHold$80.00HighView Rating Details
12/20/2017CitigroupReiterated RatingBuy -> Buy$216.00 -> $135.00LowView Rating Details
11/28/2017ArgusSet Price TargetBuy$154.00LowView Rating Details
11/15/2017Leerink SwannUpgradeMarket Perform -> OutperformN/AView Rating Details
11/10/2017SunTrust BanksReiterated RatingBuy$160.00N/AView Rating Details
11/10/2017Robert W. BairdReiterated RatingHold$120.00N/AView Rating Details
11/9/2017Lake Street CapitalReiterated RatingBuy$143.00N/AView Rating Details
11/7/2017CannReiterated RatingBuy$199.00N/AView Rating Details
11/3/2017Jefferies GroupReiterated RatingHold$124.00N/AView Rating Details
10/23/2017BarclaysInitiated CoverageEqual Weight -> Equal Weight$135.00N/AView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform$120.00MediumView Rating Details
9/11/2017WedbushReiterated RatingOutperform$160.00LowView Rating Details
9/10/2017OppenheimerReiterated RatingBuy$199.00LowView Rating Details
8/20/2017Wells Fargo & CoReiterated RatingOutperformHighView Rating Details
8/18/2017Credit Suisse GroupSet Price TargetBuy$198.00 -> $190.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$121.00HighView Rating Details
7/14/2017Janney Montgomery ScottReiterated RatingNeutralLowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$175.00HighView Rating Details
6/20/2017Raymond James FinancialReiterated RatingMarket PerformMediumView Rating Details
6/20/2017Bank of AmericaReiterated RatingBuy$154.00HighView Rating Details
6/5/2017FBR & CoLower Price TargetMkt Perform -> Mkt Perform$200.00 -> $195.00HighView Rating Details
8/5/2016MizuhoLower Price TargetBuy$100.00 -> $94.00N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

TESARO (NASDAQ:TSRO) Earnings History and Estimates Chart

Earnings by Quarter for TESARO (NASDAQ:TSRO)

TESARO (NASDAQ TSRO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($2.35)N/AView Earnings Details
11/7/2017Q3 2017($1.16)($0.47)$130.57 million$142.77 millionViewN/AView Earnings Details
8/8/2017Q2 2017($2.52)($2.82)$18.61 million$29.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($2.26)($2.55)$3.84 million$3.10 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.96)($2.60)ViewN/AView Earnings Details
11/3/2016Q3($1.92)($1.98)$4.39 million$3.73 millionViewN/AView Earnings Details
8/4/2016Q2 2016($1.69)($1.28)ViewN/AView Earnings Details
5/5/2016Q1($1.69)($2.22)$2.48 million$0.31 millionViewN/AView Earnings Details
2/25/2016Q4($1.63)($1.89)$3.45 million$0.23 millionViewListenView Earnings Details
10/29/2015Q315($1.52)($1.66)$0.09 millionViewListenView Earnings Details
8/6/2015Q215($1.14)($1.51)ViewListenView Earnings Details
4/30/2015Q115($1.12)($1.30)ViewListenView Earnings Details
2/19/2015Q414($1.03)($1.33)ViewListenView Earnings Details
11/5/2014Q314($1.04)($1.01)ViewN/AView Earnings Details
7/24/2014Q214($0.87)($1.03)ViewN/AView Earnings Details
4/30/2014Q114($1.06)($1.43)ViewN/AView Earnings Details
2/19/2014Q413($0.78)($0.72)ViewN/AView Earnings Details
11/7/2013Q313($0.69)($0.88)ViewN/AView Earnings Details
7/25/2013Q2 2013($0.63)($0.67)ViewN/AView Earnings Details
4/25/2013Q1 2013($0.62)($0.66)ViewN/AView Earnings Details
2/14/2013Q4 2012($0.65)($15.41)ViewN/AView Earnings Details
10/25/2012($0.55)($0.52)ViewN/AView Earnings Details
7/26/2012($0.55)($4.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

TESARO (NASDAQ:TSRO) Earnings Estimates

2018 EPS Consensus Estimate: ($6.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($2.17)($1.35)($1.90)
Q2 20184($1.94)($0.93)($1.61)
Q3 20184($1.94)($0.94)($1.56)
Q4 20184($1.76)($1.16)($1.43)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for TESARO (NASDAQ:TSRO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

TESARO (NASDAQ TSRO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 34.60%
Insider Trades by Quarter for TESARO (NASDAQ:TSRO)
Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

TESARO (NASDAQ TSRO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2017Martin H Jr. HuberSVPSell829$85.24$70,663.968,101View SEC Filing  
9/22/2017Martin H Jr. HuberSVPSell592$118.60$70,211.206,943View SEC Filing  
9/18/2017James O ArmitageDirectorSell10,000$117.13$1,171,300.0010,000View SEC Filing  
9/6/2017Edward C EnglishVPSell10,862$134.92$1,465,501.046,258View SEC Filing  
9/5/2017Orlando OliveiraSVPSell71$132.66$9,418.866,626View SEC Filing  
9/1/2017Grant C. BogleVPSell14,167$135.00$1,912,545.00View SEC Filing  
6/6/2017Edward C EnglishVPSell8,500$138.65$1,178,525.005,396View SEC Filing  
4/3/2017Martin H Jr. HuberSVPSell829$153.02$126,853.586,522View SEC Filing  
3/6/2017Edward C EnglishVPSell10,000$178.06$1,780,600.005,396View SEC Filing  
3/2/2017Edward C EnglishVPSell229$177.61$40,672.69625View SEC Filing  
3/2/2017Grant C. BogleSVPSell1,447$177.61$257,001.67View SEC Filing  
3/2/2017Mary Lynne HedleyCOOSell3,927$177.61$697,474.4710,000View SEC Filing  
1/3/2017Martin H. Jr. HuberSVPSell190$136.26$25,889.40View SEC Filing  
11/2/2016Martin H Jr. HuberSVPSell327$121.29$39,661.831,842View SEC Filing  
9/22/2016Martin H Jr. HuberSVPSell408$108.12$44,112.961,250View SEC Filing  
9/8/2016Edward C EnglishVPSell7,000$88.54$619,780.003,500View SEC Filing  
8/30/2016Jeffrey H HankeVPSell29,166$86.04$2,509,442.6429,166View SEC Filing  
6/30/2016Jeffrey H HankeVPSell12,500$74.35$929,375.0012,500View SEC Filing  
6/10/2016Edward C EnglishVPSell7,000$40.75$285,250.003,500View SEC Filing  
3/18/2016Arnold L OronskyDirectorBuy142,085$35.19$4,999,971.152,479View SEC Filing  
3/18/2016Enterprise Associates 13 L NewMajor ShareholderBuy710,429$35.19$24,999,996.51View SEC Filing  
3/10/2016Edward C EnglishVPSell7,000$43.71$305,970.003,500View SEC Filing  
12/10/2015Edward C. EnglishVPSell17,000$50.19$853,230.00View SEC Filing  
9/8/2015James O ArmitageDirectorBuy500$54.63$27,315.00View SEC Filing  
12/12/2014James O ArmitageDirectorBuy1,000$38.16$38,160.00View SEC Filing  
9/29/2014Lawrence M AllevaDirectorBuy1,100$26.17$28,787.00View SEC Filing  
7/31/2013Lawrence M AllevaDirectorBuy1,449$34.33$49,744.17View SEC Filing  
6/5/2013Peter J BarrisMajor ShareholderSell3,583$39.00$139,737.00View SEC Filing  
4/30/2013Lawrence M AllevaDirectorBuy1,050$28.10$29,505.00View SEC Filing  
11/1/2012Lawrence M AllevaDirectorBuy3,240$15.45$50,058.00View SEC Filing  
8/30/2012Leon O Moulder JrCEOBuy10,000$11.69$116,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

TESARO (NASDAQ TSRO) News Headlines

Source:
DateHeadline
Oversold Conditions For Tesaro (TSRO)Oversold Conditions For Tesaro (TSRO)
www.nasdaq.com - January 16 at 3:26 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tesaro, Inc. - TSROSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tesaro, Inc. - TSRO
finance.yahoo.com - January 16 at 3:26 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Tesaro, Inc. (TSRO)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Tesaro, Inc. (TSRO)
finance.yahoo.com - January 16 at 3:26 PM
TESARO (TSRO) Price Target Cut to $156.00TESARO (TSRO) Price Target Cut to $156.00
www.americanbankingnews.com - January 16 at 11:08 AM
TESARO (TSRO) Reports Increased Label Precautions to U.S. Prescribing Information for VARUBI (rolapitant) Injectable EmulsionTESARO (TSRO) Reports Increased Label Precautions to U.S. Prescribing Information for VARUBI (rolapitant) Injectable Emulsion
www.streetinsider.com - January 16 at 9:34 AM
Research Analysts Set Expectations for TESARO Incs FY2022 Earnings (TSRO)Research Analysts Set Expectations for TESARO Inc's FY2022 Earnings (TSRO)
www.americanbankingnews.com - January 15 at 4:44 PM
5 Biotech Stocks That Could Be Bought Out in 20185 Biotech Stocks That Could Be Bought Out in 2018
finance.yahoo.com - January 14 at 9:10 AM
TESAROs (TSRO) Buy Rating Reiterated at HC WainwrightTESARO's (TSRO) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - January 14 at 12:38 AM
TESARO Announces Updates to the U.S. Prescribing Information for VARUBI® (rolapitant) Injectable EmulsionTESARO Announces Updates to the U.S. Prescribing Information for VARUBI® (rolapitant) Injectable Emulsion
finance.yahoo.com - January 13 at 9:11 AM
TESARO (TSRO) Cut to "Sell" at Zacks Investment ResearchTESARO (TSRO) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 11 at 3:32 PM
Pre-Open Movers 01/02: (NETE) (WATT) (AKAO) Higher; (WFT) (TSRO) (MLCO) Lower (more...)Pre-Open Movers 01/02: (NETE) (WATT) (AKAO) Higher; (WFT) (TSRO) (MLCO) Lower (more...)
www.streetinsider.com - January 3 at 11:04 AM
 Analysts Expect TESARO Inc (TSRO) Will Announce Quarterly Sales of $51.73 Million Analysts Expect TESARO Inc (TSRO) Will Announce Quarterly Sales of $51.73 Million
www.americanbankingnews.com - January 3 at 2:34 AM
TESARO Inc (TSRO) Given Consensus Recommendation of "Buy" by BrokeragesTESARO Inc (TSRO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 2 at 7:40 PM
 Analysts Anticipate TESARO Inc (TSRO) Will Post Earnings of -$2.38 Per Share Analysts Anticipate TESARO Inc (TSRO) Will Post Earnings of -$2.38 Per Share
www.americanbankingnews.com - January 1 at 11:30 PM
Clovis Up More Than 50% in 2017: What's Driving the Stock?Clovis Up More Than 50% in 2017: What's Driving the Stock?
finance.yahoo.com - December 28 at 3:01 PM
Comparing TESARO (TSRO) and Its RivalsComparing TESARO (TSRO) and Its Rivals
www.americanbankingnews.com - December 24 at 3:22 AM
TESARO (TSRO) vs. Its Rivals Head to Head ReviewTESARO (TSRO) vs. Its Rivals Head to Head Review
www.americanbankingnews.com - December 24 at 3:22 AM
First Week of February 2018 Options Trading For Tesaro (TSRO)First Week of February 2018 Options Trading For Tesaro (TSRO)
www.nasdaq.com - December 22 at 3:49 PM
TESARO (TSRO) Earns "Buy" Rating from CitigroupTESARO (TSRO) Earns "Buy" Rating from Citigroup
www.americanbankingnews.com - December 20 at 10:10 PM
$52.32 Million in Sales Expected for TESARO Inc (TSRO) This Quarter$52.32 Million in Sales Expected for TESARO Inc (TSRO) This Quarter
www.americanbankingnews.com - December 18 at 6:24 PM
Stock Traders Purchase High Volume of TESARO Call Options (TSRO)Stock Traders Purchase High Volume of TESARO Call Options (TSRO)
www.americanbankingnews.com - December 18 at 3:10 AM
Zacks: Analysts Expect TESARO Inc (TSRO) Will Announce Earnings of -$2.38 Per ShareZacks: Analysts Expect TESARO Inc (TSRO) Will Announce Earnings of -$2.38 Per Share
www.americanbankingnews.com - December 16 at 7:30 AM
Reviewing Bellicum Pharmaceuticals (BLCM) & TESARO (TSRO)Reviewing Bellicum Pharmaceuticals (BLCM) & TESARO (TSRO)
www.americanbankingnews.com - December 16 at 5:16 AM
TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany - GlobeNewswire (press release)TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany - GlobeNewswire (press release)
globenewswire.com - December 15 at 3:29 PM
TESARO (TSRO) versus Its Peers Head to Head SurveyTESARO (TSRO) versus Its Peers Head to Head Survey
www.americanbankingnews.com - December 12 at 5:16 PM
TESARO Inc (TSRO) Given Consensus Recommendation of "Buy" by AnalystsTESARO Inc (TSRO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 8 at 9:38 PM
TESARO (TSRO) versus Its Rivals Head to Head AnalysisTESARO (TSRO) versus Its Rivals Head to Head Analysis
www.americanbankingnews.com - December 8 at 9:36 AM
Insider Selling: TESARO Inc (TSRO) SVP Sells 829 Shares of StockInsider Selling: TESARO Inc (TSRO) SVP Sells 829 Shares of Stock
www.americanbankingnews.com - December 5 at 9:52 PM
ETFs with exposure to TESARO, Inc. : December 5, 2017ETFs with exposure to TESARO, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 3:26 PM
Contrasting TESARO (TSRO) & Its RivalsContrasting TESARO (TSRO) & Its Rivals
www.americanbankingnews.com - December 2 at 7:18 PM
Tesaro Becomes Oversold (TSRO) - NasdaqTesaro Becomes Oversold (TSRO) - Nasdaq
www.nasdaq.com - December 1 at 3:30 PM
Market Trends Toward New Normal in Infinity Pharmaceuticals, Edison International, Anthem, TESARO, Brunswick, and BroadSoft — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in Infinity Pharmaceuticals, Edison International, Anthem, TESARO, Brunswick, and BroadSoft — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - December 1 at 11:22 AM
Critical Contrast: TESARO (TSRO) versus The CompetitionCritical Contrast: TESARO (TSRO) versus The Competition
www.americanbankingnews.com - November 30 at 9:30 AM
TESARO (TSRO) Given a $154.00 Price Target at ArgusTESARO (TSRO) Given a $154.00 Price Target at Argus
www.americanbankingnews.com - November 28 at 9:12 AM
TESARO Announces Availability of VARUBI® (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United StatesTESARO Announces Availability of VARUBI® (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States
finance.yahoo.com - November 28 at 8:21 AM
 Brokerages Anticipate TESARO Inc (TSRO) Will Announce Earnings of -$2.37 Per Share Brokerages Anticipate TESARO Inc (TSRO) Will Announce Earnings of -$2.37 Per Share
www.americanbankingnews.com - November 27 at 11:20 PM
ETFs with exposure to TESARO, Inc. : November 24, 2017ETFs with exposure to TESARO, Inc. : November 24, 2017
finance.yahoo.com - November 24 at 6:22 PM
TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU - NasdaqTESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU - Nasdaq
www.nasdaq.com - November 22 at 6:18 PM
TESARO Announces Participation in Two Investor Conferences - GlobeNewswire (press release)TESARO Announces Participation in Two Investor Conferences - GlobeNewswire (press release)
globenewswire.com - November 22 at 6:17 PM
TESARO Announces Participation in Two Investor ConferencesTESARO Announces Participation in Two Investor Conferences
finance.yahoo.com - November 22 at 6:17 PM
TESARO, Inc. (TSRO) Stock Rating Reaffirmed by HC WainwrightTESARO, Inc. (TSRO) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 20 at 12:04 PM
TESARO (TSRO) Announce EC Approval of ZEJULA to Treat Ovarian CancerTESARO (TSRO) Announce EC Approval of ZEJULA to Treat Ovarian Cancer
www.streetinsider.com - November 20 at 11:32 AM
TESARO, Inc. (TSRO) Upgraded to Outperform at Leerink SwannTESARO, Inc. (TSRO) Upgraded to Outperform at Leerink Swann
www.americanbankingnews.com - November 19 at 5:38 PM
TESARO, Inc. to Post FY2017 Earnings of ($8.61) Per Share, Leerink Swann Forecasts (TSRO)TESARO, Inc. to Post FY2017 Earnings of ($8.61) Per Share, Leerink Swann Forecasts (TSRO)
www.americanbankingnews.com - November 17 at 7:12 PM
Tesaro Stock Could Have 41% UpsideTesaro Stock Could Have 41% Upside
finance.yahoo.com - November 15 at 5:31 PM
ETFs with exposure to TESARO, Inc. : November 13, 2017ETFs with exposure to TESARO, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 12:09 PM
TESARO, Inc. (TSRO) Receives Consensus Rating of "Hold" from BrokeragesTESARO, Inc. (TSRO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 13 at 9:34 PM
Equities Analysts Issue Forecasts for TESARO, Inc.s FY2017 Earnings (TSRO)Equities Analysts Issue Forecasts for TESARO, Inc.'s FY2017 Earnings (TSRO)
www.americanbankingnews.com - November 13 at 1:48 AM
TESARO, Inc. (TSRO) Earns Buy Rating from SunTrust Banks, Inc.TESARO, Inc. (TSRO) Earns Buy Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - November 11 at 4:56 PM
TESAROs (TSRO) "Hold" Rating Reaffirmed at Robert W. BairdTESARO's (TSRO) "Hold" Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - November 11 at 12:10 PM

SEC Filings

TESARO (NASDAQ:TSRO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

TESARO (NASDAQ:TSRO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

TESARO (NASDAQ TSRO) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.